therasphere.com Report : Visit Site

Technical data of the therasphere.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host therasphere.com. Currently, hosted in United States and its service provider is Tiggee LLC .

the related websites

theraspheretrials.com whichmedicaldevice.com bsigroup.com prosperoequipment.com diyhomeextension.co.uk walmart.com bliss.org.uk drsfostersmith.com ibm.com road-to-the-isles.org.uk ikea.com lathes.co.uk typekit.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

cookies on the btg interventional medicine website we use cookies to ensure that we give you the best experience on your website. if you continue without changing your setting. we'll assume that you are happy to receive all cookies on the btg website. yes, continue browsing find out more btg | interventional medicine professionals (change) united kingdom (change) gb user account search menu home about us interventional oncology interventional pulmonology interventional vascular professionals (change) interventional oncology back interventional oncology back about btg im who we are 6 things about btg our manifesto a message from louise makin resources meet the expert corporate and regional press releases events noteworthy news webinars a message from louise makin, btg ceo about us interventional oncology back interventional oncology back our products dc bead ® dc bead lumi ™ dc bead m1 ® bead block ® therasphere ® galil ™ resources corporate and regional press releases events noteworthy news interventional oncology interventional oncology back interventional oncology back our products repneu ® resources corporate and regional press releases events interventional pulmonology interventional oncology back interventional oncology back our products ekos ® resources ekos catheter treatment corporate and regional press releases events noteworthy news interventional vascular what are you looking for? search the site current country selected: united kingdom current language selected: english country selector a argentina australia austria azerbaijan b bahrain belarus belgium bosnia-herzegovinia brazil brunei darussalam bulgaria c canada chile china colombia costa rica croatia cyprus czech republic d denmark dominica e egypt estonia f finland france g germany greece guatemala h hong kong hungary i iceland india indonesia ireland israel italy j japan jordan k kazakhstan korea (republic of) kuwait l latvia lebanon lithuania luxembourg m macedonia malaysia malta mexico montenegro morocco n netherlands new zealand norway o oman p panama paraguay peru philippines poland portugal q qatar r romania russian federation s saudi arabia serbia singapore slovakia slovenia south africa spain sri lanka sweden switzerland t taiwan thailand turkey u ukraine united arab emirates united kingdom united states uruguay v venezuela vietnam select your preferred language english home about support order treatment centres news & events contact interventional oncology back interventional oncology back therasphere™ about therasphere™ clinical trials radiation safety indications - ifu faqs therasphere™ bibliography benefits clinical benefits patient benefits about interventional oncology back interventional oncology back training & education centres of excellence advanced user meetings case study academy βeta™ program proctors support materials expert support medical preceptors medical preceptors form clinical research stop-hcc epoch yes-p target read 90 y registry investigator-initiated studies interventional oncology back interventional oncology back ordering information how to order therasphere online order form interventional oncology back interventional oncology back news & events events press releases noteworthy news webinars news & events interventional oncology back interventional oncology back contact us contact us contact us form contact deliver the power within discover how absorbed radiation dose to tumor maximises necrosis without compromising patient safety ^{3-6, 13, 45, 46} click to discover more stop exposing yourself to unnecessary radiation learn more simplicit⁹⁰y^™ is customised, easy-to-use dosimetry software developed for improving ⁹⁰y sirt workflow and personalising dosimetry. click to get started radiation vs. embolisation some liver cancer treatments work through their embolic properties. therasphere ™ utilises radiation as its primary mode of action to destroy tumour tissue. 1 the high activity of glass microspheres makes therasphere ™ microembolic and preserves normal parenchymal flow since fewer microspheres are needed to achieve the desired absorbed dose. 1,3,5,7,11,45 absorbed dose matters high absorbed dose coverage should be the goal of treatment with radioembolisation. influenced by the combined effects of microsphere coverage and administered activity, a greater absorbed dose to tumour with therasphere ™ leads to improved outcomes above certain absorbed dose thresholds without compromising patient safety. 1,2,5,6,39,43 power to personalize therasphere ™ offers the flexibility to optimise absorbed dose to the tumor to meet individual patient treatment goals in both the curative and palliative settings. this enables clinical utility for downstaging, bridge to transplant, radiation segmentectomy and portal vein thrombosis. 8,9,40,44 previous next therasphere™ therasphere ™ therasphere ™ yttrium-90 glass microspheres deliver a targeted radiation dose to the tumour whilst minimising exposure to healthy tissue with mild to moderate side effects. 15 find out more previous next high activity tumour necrosis improved survival high activity high activity high activity therasphere ™ glass microspheres deliver greater tumour absorbed dose coverage while resin has greater microsphere coverage. 43 tumour necrosis tumour necrosis more complete pathologic necrosis is observed when the delivered dose is >190 gy in ≤2 segments 6 -- >90% pathologic necrosis in patients resected for transplantation with high absorbed dose 2 -- median os: 56.5 months (includes transplanted patients) 34.5 months (excludes transplanted patients) improved survival improved survival total dose to the liver does not exceed 150 gy. 1 2 3 events 16 sep ilca – international liver cancer associ... 26 sep cirse – cardiovascular and interventiona... 11 oct wais - western angiographic & interventi... all events corporate and regional press releases 11 jun elevate study aims to improve selection ... 21 feb first patient in latin america receives ... 11 dec institutional decision to adopt y90 tare... all press releases noteworthy news 28 apr optalyse pe results presented at society... 17 may healthcare player btg on lookout for acq... 12 apr new procedure uses tiny beads to blast a... all news about btg about btg about btg im visit btg plc website contact btg legal legal legal notice disclaimer privacy policy and cookies consent management useful links useful links accessibility linkedin twitter btg linkedin twitter in the eu, therasphere™ is used in the treatment of hepatic neoplasia. in canada, therasphere™ may be used in the treatment of hepatic neoplasia patients who have appropriately positioned arterial catheters. common adverse effects include fatigue, pain, and nausea. the majority of adverse effects were mild to moderate in severity and were manageable or resolved over time. for details on rare or more severe adverse effects, please refer to the therasphere™ instructions for use at www.therasphere.com . 2,3,47,48 view all references therasphere™ yttrium-90 glass microspheres – instructions for use – english, #990252. spe rev. 8. biocompatibles uk ltd, a btg international group company. walrand s, hesse m, jamar f, et al. a hepatic dose-toxicity model opening the way toward individualized radioembolization planning. j nucl med 2014;55(8):1317–22. hilgard p, hamami m, fouly ae, et al. radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: european experience on safety and long-term survival. hepatology 2010;52(5):1741–9. riaz a, gates vl, atassi b, et al. radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. int j radiat oncol biol phys 2011;79(1):163–71 mazzaferro v, sposito c, bhoori s, et al. yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. hepatology 2013;57(5):1826–

URL analysis for therasphere.com

https://www.btg-im.com/en-GB/TheraSphere/Home/therasphere/about/therasphere/radiation-safety
https://www.btg-im.com/en-GB/TheraSphere/Home/patients-and-carers
https://www.btg-im.com/en-GB/TheraSphere/Home/en-sk/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/en-my/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/en-dm/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/en-br/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/interventional-vascular/noteworthy-news
https://www.btg-im.com/en-GB/TheraSphere/Home/resources/login.aspx
https://www.btg-im.com/en-GB/TheraSphere/Home/en-pt/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/en-cn/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/en-in/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/en-gb/interventional-vascular
https://www.btg-im.com/en-GB/TheraSphere/Home/privacy-policy-and-cookies
https://www.btg-im.com/en-GB/TheraSphere/Home/en-ma/therasphere/home
https://www.btg-im.com/en-GB/TheraSphere/Home/therasphere/news-events

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: THERASPHERE.COM
Registry Domain ID: 2785777_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2016-04-12T04:25:36Z
Creation Date: 1998-12-17T05:00:00Z
Registry Expiry Date: 2020-12-17T05:00:00Z
Registrar: MarkMonitor Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS10.DNSMADEEASY.COM
Name Server: NS11.DNSMADEEASY.COM
Name Server: NS12.DNSMADEEASY.COM
Name Server: NS13.DNSMADEEASY.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-12T18:49:31Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR MarkMonitor Inc.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =therasphere.com

  PORT 43

  TYPE domain

DOMAIN

  NAME therasphere.com

  CHANGED 2016-04-12

  CREATED 1998-12-17

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS10.DNSMADEEASY.COM 208.94.148.4

  NS11.DNSMADEEASY.COM 208.80.124.4

  NS12.DNSMADEEASY.COM 208.80.126.4

  NS13.DNSMADEEASY.COM 208.80.125.4

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .